Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

29.11.2024 11:30:00 CET | news aktuell GmbH | Press release

Share
  • Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
  • Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board
Oren Weininger, CEO Copyright Strides Pharma International AG.
Oren Weininger, CEO Copyright Strides Pharma International AG.

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.

Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.

The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.

Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”

Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.

For further information, please visit: www.fair-med.com/newsroom

Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690

Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.

Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.

Images

Oren Weininger, CEO Copyright Strides Pharma International AG.
Oren Weininger, CEO Copyright Strides Pharma International AG.
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Munich Arena breaks ground, marking a new era for live music in Europe30.10.2026 09:00:53 CET | Press release

20,000 capacity "Music first" venue: The Munich Arena will be Germany's first concert arena specifically designed for music and live entertainment. The combination of striking architecture, exceptional acoustics, excellent sightlines, premium hospitality and world-class production facilities for artists and promoters will make Munich Arena one of Europe’s leading live music venues. Economic impact of €355 million per year: Munich Arena will boost the economy and culture for Munich and Bavaria, a Deloitte study estimates the economic impact to be around €355 million per year when the venue is open. Countdown to the opening in 2029 has begun: Freising’s lord mayor Monika Schwind joined Marek Lieberberg, President Live Nation GSA, Tom Lynch, President Live Nation Venues, Lorenz Schmid, Managing Partner Munich Arena, and Bavarian Prime Minister Dr. Markus Söder to officially break ground on Munich Arena. A supporter of Munich’s Olympic concept and the Free State of Bavaria:. Munich Arena i

Flamingo-1: Germany’s First Space-Based SDA Telescope Delivers Commercial Space Surveillance and Tracking29.10.2026 10:39:13 CET | Press release

(Munich, Germany) – Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has entered routine operations with its Flamingo-1 satellite. The satellite operates at a high duty cycle, continuously monitoring space objects, scouting for threats from low Earth orbit (LEO) to geostationary Earth orbit (GEO). The space-based image data generated by Flamingo-1 is further processed by Vyoma into products, services and intelligence in high demand among the SDA community and Vyoma’s customers to better understand the space domain from both a safety and a security perspective. The information is delivered to the company’s customers through the Vyoma Services Platform. Flamingo-1 operates both in surveillance and in tracking mode. In surveillance mode, the satellite continuously screens a large volume of space, setting it apart from ground-based optical systems that are idle during the day or when obstructed by bad weather. This high volume of data is ideal for creatin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye